KR102083041B1 - 술폰아미드 화합물 및 tnap 억제제로서 용도 - Google Patents
술폰아미드 화합물 및 tnap 억제제로서 용도 Download PDFInfo
- Publication number
- KR102083041B1 KR102083041B1 KR1020147025901A KR20147025901A KR102083041B1 KR 102083041 B1 KR102083041 B1 KR 102083041B1 KR 1020147025901 A KR1020147025901 A KR 1020147025901A KR 20147025901 A KR20147025901 A KR 20147025901A KR 102083041 B1 KR102083041 B1 KR 102083041B1
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- compound
- nmr
- dmso
- brs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(C=C1)=**1O Chemical compound *C(C=C1)=**1O 0.000 description 2
- COBFXKQTPDISMX-UHFFFAOYSA-N CC(C)CNS(C=C)(O)O Chemical compound CC(C)CNS(C=C)(O)O COBFXKQTPDISMX-UHFFFAOYSA-N 0.000 description 1
- ZFHJROCBFSIMGS-UHFFFAOYSA-N CCCNC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O Chemical compound CCCNC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O ZFHJROCBFSIMGS-UHFFFAOYSA-N 0.000 description 1
- BKTDXOIWVXDOQC-UHFFFAOYSA-N CCCNC(c(cc1)cc(S(Nc2cnc(cccc3)c3c2)(=O)=O)c1OC)=O Chemical compound CCCNC(c(cc1)cc(S(Nc2cnc(cccc3)c3c2)(=O)=O)c1OC)=O BKTDXOIWVXDOQC-UHFFFAOYSA-N 0.000 description 1
- MNNSHGXODXRQKK-UHFFFAOYSA-N CCCNC(c1cncc(NS(c(cc(cc2)OC(F)(F)F)c2OC)(=O)=O)c1)=O Chemical compound CCCNC(c1cncc(NS(c(cc(cc2)OC(F)(F)F)c2OC)(=O)=O)c1)=O MNNSHGXODXRQKK-UHFFFAOYSA-N 0.000 description 1
- SEZHZPFZGABNFD-FPICKTPQSA-N CCCNOC(CC)NS(C[C@@H](/C=C\C(Br)=C)OC)(O)O Chemical compound CCCNOC(CC)NS(C[C@@H](/C=C\C(Br)=C)OC)(O)O SEZHZPFZGABNFD-FPICKTPQSA-N 0.000 description 1
- SOAROBGXXGZBLF-UHFFFAOYSA-N CCNC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O Chemical compound CCNC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O SOAROBGXXGZBLF-UHFFFAOYSA-N 0.000 description 1
- XXACBGIQNCQOJU-UHFFFAOYSA-N CCNC(c(cc1)cc(S(Nc2cnc(cccc3)c3c2)(=O)=O)c1OC)=O Chemical compound CCNC(c(cc1)cc(S(Nc2cnc(cccc3)c3c2)(=O)=O)c1OC)=O XXACBGIQNCQOJU-UHFFFAOYSA-N 0.000 description 1
- TYDJBDCSRPKAKV-UHFFFAOYSA-N CCNC(c1cncc(NS(c(cc(cc2)Br)c2OC)(=O)=O)c1)=O Chemical compound CCNC(c1cncc(NS(c(cc(cc2)Br)c2OC)(=O)=O)c1)=O TYDJBDCSRPKAKV-UHFFFAOYSA-N 0.000 description 1
- LNRMRMNMHWNGSB-UHFFFAOYSA-N CN(C)CCN(c1cnc(cccc2)c2c1)S(c1cc(OC)ccc1OC)(=O)=O Chemical compound CN(C)CCN(c1cnc(cccc2)c2c1)S(c1cc(OC)ccc1OC)(=O)=O LNRMRMNMHWNGSB-UHFFFAOYSA-N 0.000 description 1
- IPSDJFQHVXDRAY-UHFFFAOYSA-N CN(C)CCNc(nc1)ccc1NS(c(cc(cc1)OC)c1OC)(=O)=O Chemical compound CN(C)CCNc(nc1)ccc1NS(c(cc(cc1)OC)c1OC)(=O)=O IPSDJFQHVXDRAY-UHFFFAOYSA-N 0.000 description 1
- NXSSJXYRALFNHC-UHFFFAOYSA-N CN(C)c(nc1)ccc1NS(c(cc(cc1)Br)c1OC)(=O)=O Chemical compound CN(C)c(nc1)ccc1NS(c(cc(cc1)Br)c1OC)(=O)=O NXSSJXYRALFNHC-UHFFFAOYSA-N 0.000 description 1
- KNBQWTPDXPJPFD-UHFFFAOYSA-N CN(CC1)CCN1c(nc1)ccc1NS(c(cc(cc1)Br)c1OC)(=O)=O Chemical compound CN(CC1)CCN1c(nc1)ccc1NS(c(cc(cc1)Br)c1OC)(=O)=O KNBQWTPDXPJPFD-UHFFFAOYSA-N 0.000 description 1
- ANUQUWCLOFAVSL-UHFFFAOYSA-N CN(CC1)CCN1c(nc1)ccc1NS(c(cc(cc1)OC)c1OC)(=O)=O Chemical compound CN(CC1)CCN1c(nc1)ccc1NS(c(cc(cc1)OC)c1OC)(=O)=O ANUQUWCLOFAVSL-UHFFFAOYSA-N 0.000 description 1
- JHTLYXXPGKCOSX-UHFFFAOYSA-N CNC(c1cc(NS(c(cc(cc2)Cl)c2OC)(=O)=O)cnc1)=O Chemical compound CNC(c1cc(NS(c(cc(cc2)Cl)c2OC)(=O)=O)cnc1)=O JHTLYXXPGKCOSX-UHFFFAOYSA-N 0.000 description 1
- OGOXRPWCVJABIF-UHFFFAOYSA-N COC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O Chemical compound COC(c(cc1)cc(S(Nc2cccnc2)(=O)=O)c1OC)=O OGOXRPWCVJABIF-UHFFFAOYSA-N 0.000 description 1
- MMKYNJCDSGABOZ-UHFFFAOYSA-N COC(c(cc1S(Nc2cnc(cccc3)c3c2)(=O)=O)ccc1OC)=O Chemical compound COC(c(cc1S(Nc2cnc(cccc3)c3c2)(=O)=O)ccc1OC)=O MMKYNJCDSGABOZ-UHFFFAOYSA-N 0.000 description 1
- AXSANZPLIQVYDN-UHFFFAOYSA-N COC(c1cc(NS(c(cc(cc2)Cl)c2OC)(=O)=O)cnc1)=O Chemical compound COC(c1cc(NS(c(cc(cc2)Cl)c2OC)(=O)=O)cnc1)=O AXSANZPLIQVYDN-UHFFFAOYSA-N 0.000 description 1
- OVUMKLXXHBLZSU-UHFFFAOYSA-N COCCNC(c1cc(NS(c(cc(cc2)Br)c2OC)(=O)=O)cnc1)=O Chemical compound COCCNC(c1cc(NS(c(cc(cc2)Br)c2OC)(=O)=O)cnc1)=O OVUMKLXXHBLZSU-UHFFFAOYSA-N 0.000 description 1
- RTCYFSCEIGGDNM-UHFFFAOYSA-N COc(c(S(Nc1cc(cc(cc2)C(O)=O)c2nc1)(=O)=O)c1)ccc1Br Chemical compound COc(c(S(Nc1cc(cc(cc2)C(O)=O)c2nc1)(=O)=O)c1)ccc1Br RTCYFSCEIGGDNM-UHFFFAOYSA-N 0.000 description 1
- WKLIYRLWABCPHX-UHFFFAOYSA-N COc(c(S(Nc1cncc(-c(cc2)ccc2F)c1)(=O)=O)c1)ccc1Cl Chemical compound COc(c(S(Nc1cncc(-c(cc2)ccc2F)c1)(=O)=O)c1)ccc1Cl WKLIYRLWABCPHX-UHFFFAOYSA-N 0.000 description 1
- YJZXUZUNTSWHPM-UHFFFAOYSA-N COc(c(S(Nc1cncc(-c2ccccc2Cl)c1)(=O)=O)c1)ccc1Br Chemical compound COc(c(S(Nc1cncc(-c2ccccc2Cl)c1)(=O)=O)c1)ccc1Br YJZXUZUNTSWHPM-UHFFFAOYSA-N 0.000 description 1
- AOCNQRNPQJCMDX-UHFFFAOYSA-N COc(cc1)cc(S(Nc2cc(-c3cccnc3)cnc2)(=O)=O)c1OC Chemical compound COc(cc1)cc(S(Nc2cc(-c3cccnc3)cnc2)(=O)=O)c1OC AOCNQRNPQJCMDX-UHFFFAOYSA-N 0.000 description 1
- GSJUYLFAODJCMV-UHFFFAOYSA-N COc(cc1)ccc1-c1cc(NS(c2cc(Cl)ccc2OC)(=O)=O)cnc1 Chemical compound COc(cc1)ccc1-c1cc(NS(c2cc(Cl)ccc2OC)(=O)=O)cnc1 GSJUYLFAODJCMV-UHFFFAOYSA-N 0.000 description 1
- RQPQEVWTLKEQHP-UHFFFAOYSA-N COc(cc1S(Nc2cncc(C(Nc3ccccc3)=O)c2)(=O)=O)ccc1OC Chemical compound COc(cc1S(Nc2cncc(C(Nc3ccccc3)=O)c2)(=O)=O)ccc1OC RQPQEVWTLKEQHP-UHFFFAOYSA-N 0.000 description 1
- OZHZDYLKZUEHPK-UHFFFAOYSA-N COc(ccc(Br)c1)c1S(Nc1ccc(N2CCOCC2)nc1)(=O)=O Chemical compound COc(ccc(Br)c1)c1S(Nc1ccc(N2CCOCC2)nc1)(=O)=O OZHZDYLKZUEHPK-UHFFFAOYSA-N 0.000 description 1
- QKJAECLCIDIAAS-UHFFFAOYSA-N COc(ccc(Br)c1)c1S(Nc1cncc(-c2ccc(C(F)(F)F)cc2)c1)(=O)=O Chemical compound COc(ccc(Br)c1)c1S(Nc1cncc(-c2ccc(C(F)(F)F)cc2)c1)(=O)=O QKJAECLCIDIAAS-UHFFFAOYSA-N 0.000 description 1
- XUWHHZNQBHWGSW-UHFFFAOYSA-N COc(ccc(Br)c1)c1S(Nc1cncc(-c2cccc(Cl)c2)c1)(=O)=O Chemical compound COc(ccc(Br)c1)c1S(Nc1cncc(-c2cccc(Cl)c2)c1)(=O)=O XUWHHZNQBHWGSW-UHFFFAOYSA-N 0.000 description 1
- XTMQNWNWANDPIT-UHFFFAOYSA-N COc(ccc(Br)c1)c1S(Nc1cncc(-c2ccncc2)c1)(=O)=O Chemical compound COc(ccc(Br)c1)c1S(Nc1cncc(-c2ccncc2)c1)(=O)=O XTMQNWNWANDPIT-UHFFFAOYSA-N 0.000 description 1
- FFAKCSFQQCVHHV-UHFFFAOYSA-N COc(ccc(C(O)=O)c1)c1S(Nc1cccnc1)(=O)=O Chemical compound COc(ccc(C(O)=O)c1)c1S(Nc1cccnc1)(=O)=O FFAKCSFQQCVHHV-UHFFFAOYSA-N 0.000 description 1
- QARYUOFTNHSBTR-UHFFFAOYSA-N COc(ccc(C(O)=O)c1)c1S(Nc1cnc(cccc2)c2c1)(=O)=O Chemical compound COc(ccc(C(O)=O)c1)c1S(Nc1cnc(cccc2)c2c1)(=O)=O QARYUOFTNHSBTR-UHFFFAOYSA-N 0.000 description 1
- XMMMJTFMNRHATR-UHFFFAOYSA-N COc(ccc(Cl)c1)c1S(Nc1cc(-c2ccc(C(F)(F)F)cc2)cnc1)(=O)=O Chemical compound COc(ccc(Cl)c1)c1S(Nc1cc(-c2ccc(C(F)(F)F)cc2)cnc1)(=O)=O XMMMJTFMNRHATR-UHFFFAOYSA-N 0.000 description 1
- OKVFVOYJIRYFKY-QHNMEFLSSA-N C[C@@H](CCS(C)(=O)=O)/C(/COC)=C\[C@@H](C)Br Chemical compound C[C@@H](CCS(C)(=O)=O)/C(/COC)=C\[C@@H](C)Br OKVFVOYJIRYFKY-QHNMEFLSSA-N 0.000 description 1
- OZHPJXJWRAQWRN-UHFFFAOYSA-N Cc1cc(-c2cc(NS(c3cc(Cl)ccc3OC)(=O)=O)cnc2)ccc1 Chemical compound Cc1cc(-c2cc(NS(c3cc(Cl)ccc3OC)(=O)=O)cnc2)ccc1 OZHPJXJWRAQWRN-UHFFFAOYSA-N 0.000 description 1
- SCAOQXKDBVXMGA-UHFFFAOYSA-N Cc1ccccc1-c1cc(NS(c2cc(OC)ccc2OC)(=O)=O)cnc1 Chemical compound Cc1ccccc1-c1cc(NS(c2cc(OC)ccc2OC)(=O)=O)cnc1 SCAOQXKDBVXMGA-UHFFFAOYSA-N 0.000 description 1
- VVTSPTCBHTWXMD-UHFFFAOYSA-N Nc1ccc(N2CCOCC2)nc1 Chemical compound Nc1ccc(N2CCOCC2)nc1 VVTSPTCBHTWXMD-UHFFFAOYSA-N 0.000 description 1
- GCMPJXFIWZYGPG-UHFFFAOYSA-N O=S(c1cc(Cl)ccc1OC(F)(F)F)(Nc1cc(-c2cnc[s]2)cnc1)=O Chemical compound O=S(c1cc(Cl)ccc1OC(F)(F)F)(Nc1cc(-c2cnc[s]2)cnc1)=O GCMPJXFIWZYGPG-UHFFFAOYSA-N 0.000 description 1
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N [O-][N+](c(cc1)cnc1Cl)=O Chemical compound [O-][N+](c(cc1)cnc1Cl)=O BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 1
- FYJXIPHXFGFEGT-UHFFFAOYSA-N [O-][N+](c1ccc(N2CCOCC2)nc1)=O Chemical compound [O-][N+](c1ccc(N2CCOCC2)nc1)=O FYJXIPHXFGFEGT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/42—Benzene-sulfonamido pyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601957P | 2012-02-22 | 2012-02-22 | |
| US61/601,957 | 2012-02-22 | ||
| PCT/US2013/027191 WO2013126608A1 (en) | 2012-02-22 | 2013-02-21 | Sulfonamide compounds and uses as tnap inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140129191A KR20140129191A (ko) | 2014-11-06 |
| KR102083041B1 true KR102083041B1 (ko) | 2020-05-27 |
Family
ID=49006214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147025901A Expired - Fee Related KR102083041B1 (ko) | 2012-02-22 | 2013-02-21 | 술폰아미드 화합물 및 tnap 억제제로서 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9458147B2 (enExample) |
| EP (1) | EP2817292B1 (enExample) |
| JP (2) | JP6302846B2 (enExample) |
| KR (1) | KR102083041B1 (enExample) |
| CN (1) | CN104334527B (enExample) |
| AU (1) | AU2013222345B2 (enExample) |
| BR (1) | BR112014020773A2 (enExample) |
| CA (1) | CA2865071C (enExample) |
| RU (1) | RU2627701C2 (enExample) |
| WO (1) | WO2013126608A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3721880T3 (pl) | 2010-09-01 | 2022-05-23 | Thomas Jefferson University | Kompozycja i sposób naprawy i regeneracji mięśni |
| EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
| US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN103755628B (zh) * | 2014-01-27 | 2015-07-29 | 河北科技大学 | 2-氨基-3-碘-5-溴吡啶的合成方法 |
| WO2016054056A1 (en) * | 2014-10-01 | 2016-04-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating pxe with tnap inhibitors |
| US9920068B2 (en) * | 2015-07-08 | 2018-03-20 | Daiichi Sankyo Company, Limited | Pyridine compounds |
| ITUA20161994A1 (it) * | 2016-03-24 | 2017-09-24 | Azienda Ospedaliera Univ Senese | Uso degli inibitori ddx3 come agenti anti-iperproliferativi |
| ES2963348T3 (es) | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| WO2018119449A1 (en) | 2016-12-23 | 2018-06-28 | Daiichi Sankyo Company, Limited | Oxazepine derivatives having tnap inhibitory activity |
| WO2018119444A1 (en) | 2016-12-23 | 2018-06-28 | Daiichi Sankyo Company, Limited | Sulfonamide compounds having tnap inhibitory activity |
| JP2021532376A (ja) * | 2018-07-10 | 2021-11-25 | アカデミア シニカAcademia Sinica | 強直性脊椎炎の診断、予後および治療のためのバイオマーカーおよび標的 |
| BR112021007261A2 (pt) | 2018-10-23 | 2021-08-10 | Daiichi Sankyo Company, Limited | composto, composição farmacêutica, inibidor de fosfatase alcalina de tecido não específica, métodos para inibir fosfatase alcalina de tecido não específica, para a profilaxia ou tratamento de calcificação ectópica e de uma doença ou condição, e, uso de um composto |
| US12453738B2 (en) | 2019-03-12 | 2025-10-28 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| IL293545A (en) | 2019-12-04 | 2022-08-01 | Univ Leland Stanford Junior | Enhancing blood-brain barrier drug transport by targeting endogenous regulators |
| CN113683563B (zh) * | 2021-08-31 | 2024-01-30 | 合肥工业大学 | 一种多取代3-磺酰胺喹啉化合物的合成方法 |
| CN115837023B (zh) * | 2023-02-20 | 2023-05-16 | 中山大学附属第八医院(深圳福田) | 1-甲基烟酰胺在制备抗血管钙化药物中的应用 |
| KR102790313B1 (ko) * | 2023-11-07 | 2025-04-04 | 주식회사 레드엔비아 | Tnap 저해 화합물 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW352384B (en) * | 1992-03-24 | 1999-02-11 | Hoechst Ag | Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| JP4039856B2 (ja) * | 2000-02-03 | 2008-01-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インテグリン発現阻害剤 |
| US7053071B2 (en) * | 2001-11-30 | 2006-05-30 | The Burnham Institute | Induction of apoptosis in cancer cells |
| GB0206219D0 (en) * | 2002-03-15 | 2002-05-01 | Ferring Bv | Non-Peptide GnRH antagonists |
| WO2004018461A2 (en) * | 2002-08-23 | 2004-03-04 | Pharmacia & Upjohn Company Llc | Antibacterial benzoic acid derivatives |
| US20040110802A1 (en) * | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| PT1562940E (pt) | 2002-11-18 | 2007-07-23 | Chemocentryx Inc | Sulfonamidas de arilo. |
| PT1789041E (pt) * | 2004-07-28 | 2008-08-20 | Hoffmann La Roche | Derivados de aril-piridina |
| US20090142347A1 (en) * | 2004-09-29 | 2009-06-04 | The Burnham Institute For Medical Research | Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification |
| SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| JP2008519814A (ja) * | 2004-11-12 | 2008-06-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物 |
| GB0425026D0 (en) * | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
| CA2599555A1 (en) * | 2005-03-16 | 2006-09-21 | Basf Aktiengesellschaft | Biphenyl-n-(4-pyridyl) methylsufonamides |
| WO2007014008A2 (en) * | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| EP1987002A1 (en) | 2006-02-14 | 2008-11-05 | Basf Se | Pyridin-4 -ylmethylamides for combating pests |
| JP2009535388A (ja) * | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | ピラゾール誘導体、及びそのpi3k阻害薬としての使用 |
| WO2007129044A1 (en) * | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Thiazole derivatives and their use as anti-tumour agents |
| WO2008028937A1 (en) * | 2006-09-08 | 2008-03-13 | Novartis Ag | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| WO2009017863A2 (en) | 2007-05-08 | 2009-02-05 | Burnham Institute For Medical Research | Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification |
| US20090053192A1 (en) * | 2007-08-10 | 2009-02-26 | Burnham Institute For Medical Research | Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof |
| US8039493B2 (en) * | 2007-09-27 | 2011-10-18 | Hoffmann-La Roche Inc. | Biaryl sulfonamide derivatives |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| JP2011521916A (ja) * | 2008-05-19 | 2011-07-28 | バーナム インスティテュート フォー メディカル リサーチ | 腸アルカリホスファターゼモジュレーターおよびそれの使用 |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| WO2010038081A2 (en) * | 2008-10-03 | 2010-04-08 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| PT2429995E (pt) * | 2009-05-15 | 2014-04-30 | Novartis Ag | Arilpiridinas como inibidores de aldosterona sintase |
| SG177434A1 (en) * | 2009-06-29 | 2012-02-28 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
| FR2970967B1 (fr) * | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
| WO2016054056A1 (en) * | 2014-10-01 | 2016-04-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods of treating pxe with tnap inhibitors |
-
2013
- 2013-02-21 EP EP13752050.8A patent/EP2817292B1/en active Active
- 2013-02-21 WO PCT/US2013/027191 patent/WO2013126608A1/en not_active Ceased
- 2013-02-21 BR BR112014020773-9A patent/BR112014020773A2/pt not_active Application Discontinuation
- 2013-02-21 KR KR1020147025901A patent/KR102083041B1/ko not_active Expired - Fee Related
- 2013-02-21 US US14/379,475 patent/US9458147B2/en active Active
- 2013-02-21 AU AU2013222345A patent/AU2013222345B2/en active Active
- 2013-02-21 CA CA2865071A patent/CA2865071C/en active Active
- 2013-02-21 JP JP2014558836A patent/JP6302846B2/ja active Active
- 2013-02-21 CN CN201380021207.0A patent/CN104334527B/zh active Active
- 2013-02-21 RU RU2014137402A patent/RU2627701C2/ru active
-
2016
- 2016-08-19 US US15/241,905 patent/US9884826B2/en active Active
-
2018
- 2018-01-11 JP JP2018002991A patent/JP6544545B2/ja active Active
- 2018-02-05 US US15/888,736 patent/US10370333B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| Journal of Medicinal Chemistry, 52(21), 6919-6925쪽(2009.) |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1203958A1 (en) | 2015-11-06 |
| JP2018104434A (ja) | 2018-07-05 |
| BR112014020773A2 (pt) | 2020-10-27 |
| RU2627701C2 (ru) | 2017-08-10 |
| EP2817292B1 (en) | 2019-12-18 |
| JP2015508102A (ja) | 2015-03-16 |
| US20160355479A1 (en) | 2016-12-08 |
| EP2817292A4 (en) | 2015-08-26 |
| AU2013222345B2 (en) | 2017-09-07 |
| US9884826B2 (en) | 2018-02-06 |
| EP2817292A1 (en) | 2014-12-31 |
| CN104334527B (zh) | 2017-05-24 |
| CN104334527A (zh) | 2015-02-04 |
| US10370333B2 (en) | 2019-08-06 |
| AU2013222345A1 (en) | 2014-09-11 |
| US20150011551A1 (en) | 2015-01-08 |
| RU2014137402A (ru) | 2016-04-10 |
| WO2013126608A1 (en) | 2013-08-29 |
| US20190010126A1 (en) | 2019-01-10 |
| US9458147B2 (en) | 2016-10-04 |
| JP6544545B2 (ja) | 2019-07-17 |
| KR20140129191A (ko) | 2014-11-06 |
| CA2865071C (en) | 2020-06-23 |
| JP6302846B2 (ja) | 2018-03-28 |
| CA2865071A1 (en) | 2013-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102083041B1 (ko) | 술폰아미드 화합물 및 tnap 억제제로서 용도 | |
| JP5112423B2 (ja) | ピリドピリミジノン誘導体 | |
| JP2022529615A (ja) | Mas関連gタンパク質受容体x4のモジュレーターおよび関連製品ならびに方法 | |
| JP2021507897A (ja) | Lpaアンタゴニストとしてのピラゾールo−架橋カルバモイルシクロヘキシル酸 | |
| JP6505222B2 (ja) | ヒストンリジン脱メチル化触媒活性を調節するための新規ピリドピリミジノン化合物 | |
| JP6713928B2 (ja) | Urat1阻害剤 | |
| JP2017537937A (ja) | 線維症の小分子阻害剤 | |
| JP2023523545A (ja) | Mas関連Gタンパク質受容体X4のモジュレーター、関連製品及びその使用方法 | |
| JP2011503042A (ja) | p38MAPキナーゼ阻害剤 | |
| MX2012005189A (es) | Inhibidores de ire-1-alfa. | |
| JP2020503334A (ja) | ピリミジン化合物 | |
| WO2017034377A1 (en) | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) | |
| ES2691548T3 (es) | Sales de moduladores de PPAR y métodos para tratar desórdenes metabólicos | |
| HK1203958B (en) | Sulfonamide compounds and uses as tnap inhibitors | |
| RU2815715C2 (ru) | Модуляторы связанных с mas рецепторов g-белка x4 и связанные с ними продукты и способы | |
| CN109232426A (zh) | 一种n-羟基-5-取代-1h-吡唑-3-甲酰胺化合物及其制备方法和用途 | |
| KR101446738B1 (ko) | 4-티오피라졸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상지질혈증의 예방 또는 치료용 약학적 조성물 | |
| WO2020013116A1 (ja) | Ptp-1b阻害剤およびその用途 | |
| JPH0892222A (ja) | N−フェニルアミド及び尿素誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20230225 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20230225 |